Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer
Frontiers in Oncology · 13.03.2026 · 16
DOI: 10.3389/fonc.2026.1574236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 13.03.2026. Verfasst von Xiabing Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Ovarian cancer (OC) is one of the most common gynecological malignancies with an extremely poor prognosis. Among them, epithelial ovarian cancer (EOC) is the most common histological type and exhibits more aggressive behavior. Non-SMC condensin II complex subunit G2 (NCAPG2) is crucial for the execution of chromosomal mitosis and the promotion of tumorigenesis, but its role in the progression of EOC remains unclear.
Method
In this study, we first analyzed the expression of NCAPG2 in EOC using data from the cancer genome atlas program (TCGA) database, Genotype-Tissue Expression (GTEx) project, and the Gene Expression Omnibus (GEO) dataset (GSE9891). Subsequently, bioinformatics tools were used to explore the expression of NCAPG2 in EOC and its related functions. In addition, we also evaluated the role of NCAPG2 in DNA damage repair, chemotherapy resistance, immune cell infiltration, and immunotherapy response. Finally, its expression and function have been verified through clinical samples and in vitro experiments.
Result
Analyses of databases revealed that NCAPG2 is significantly overexpressed in EOC tissues and cells. NCAPG2 plays a role in DNA damage repair, chemotherapy resistance, immune cell infiltration, and immunotherapy response. More importantly, knockdown of NCAPG2 by siRNA can inhibit the proliferation, migration, and invasion abilities of EOC cells A2780 and OVCAR3 in vitro through the epithelial-mesenchymal transition (EMT) signaling pathway. Clinical specimens have confirmed that NCAPG2 is highly expressed in EOC tissues and is closely related to the clinical stage.
Conclusion
High expression of NCAPG2 can promote the progression of EOC and may serve as a potential novel therapeutic target for EOC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gynecologic Oncology, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Gynecologic Oncology, Zhengzhou Key Laboratory of Gynecological Oncology, Zhengzhou, Henan, China.
- Gynecologic Oncology, The International Joint Laboratory of Ovarian Malignant Tumor, Zhengzhou, Henan, China.
Förderung
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Li, X., Wang, Y., Kang, L., Zhu, H., Liu, Q., & Li, H. (2026). Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1574236
Vancouver
Li X, Wang Y, Kang L, Zhu H, Liu Q, Li H. Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1574236
BibTeX
@article{Li2026,
author = {Li, Xiabing and Wang, Yaping and Kang, Luyao and Zhu, Hai and Liu, Qing and Li, Hongyu},
title = {Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1574236}
}
EUVIMED